The need for child-specific knowledge acquisition through high-quality clinical trials is clear. Due to differences in drug metabolism or pathophysiology, children may respond differently than adults to various therapies, even when used to treat the same disease.1 This is reflected in the stated need from regulators, such as the US Food and Drug Administration (FDA), for child-specific knowledge generation. As the COVID-19 pandemic has demonstrated, it has been difficult to generate child-specific data in a timeframe that is scientifically robust and clinically actionable.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Murthy S, Fontela P, Berry S. Incorporating Adult Evidence Into Pediatric Research and Practice: Bayesian Designs to Expedite Obtaining Child-Specific Evidence. JAMA. 2021;325(19):1937–1938. doi:10.1001/jama.2020.25007
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: